ASPIRE: Treating Children With Atopic Dermatitis (Eczema)
Research Question:
How do topical medications for atopic dermatitis affect health and quality of life
in children and their caregivers?
Basic Study Information
Purpose:
Researchers are seeking to understand how two standard topical treatments for atopic
dermatitis
affect patient-reported outcomes (itch, pain, sleep, mood, and quality of life) and
parent/caregiver
quality of life. Participation will last approximately 12 weeks, which will include
3 clinic visits at UR Dermatology for clinical assessment of atopic dermatitis and
the completion of electronic questionnaires by the child with atopic dermatitis and
a parent/caregiver. Payment for participation is up to $130 if all visits are completed.
You may be eligible if: You have a child between 2 to 15 years of age with a clinical
diagnosis of mild to moderate Atopic Dermatitis. Your child does not have a diagnosis
of another skin disease.
Location: University of Rochester Dermatology
Study Reference #: 00073062
Lead Researcher (Principal Investigator)
Lead Researcher:
Julie Wolf
Study Contact Information
Study Coordinator: Alicia Papilia
Phone: (585) 273-4195
Email: Alicia_Papalia@urmc.rochester.edu
Additional Study Details
Study Details:
This is an open-label, randomized, cross-sectional study to monitor the effects of
crisaborole and tacrolimus 0.03% on patient-reported outcomes (PROs) and caregiver
burden in children (ages 5 to 15 years, inclusive) with mild to moderate atopic dermatitis
over a 12 week period of time. The goal of this study is to detect changes in PROs
and caregiver burden during treatment for atopic dermatitis of moderate or less severity.
The study design will allow us to correlate PROs and caregiver burden with treatment
response and disease improvement in children.
Children with mild to moderate atopic dermatitis (ages 5 to 15 years, inclusive) are
eligible. Their parent or caregiver must also participate in the study with the child
participant. The child will be randomized to tacrolimus 0.03% or crisaborole for their
atopic dermatitis which they will use for 12 weeks. The study consists of 3 clinic
visits over 12 weeks (baseline, 6 weeks, 12 weeks) during which the child's atopics
dermatitis will be clinically assessed and the child and caregiver/parent will complete
a questionnaire on an iPad. Subjects will be reimbursed for their participation in
this study.
Number of Visits:
2 to 5
Parking:
Free
Transportation Coverage:
No
Reimbursement:
Yes
Payment Details:
Child participants will receive a $10 gift card at the end of each study visit for
their participation. All adult caregiver subjects will be reimbursed $100 for completion
of all study procedures. Payment will be prorated based on number of assessments completed
in the study. Subjects will be paid $20 for completion of Baseline Assessment, $40
for completion of 6 Week Assessment, and $40 for completion of 12 Week Assessment.
A check will be issued to the adult caregiver (i.e., caregiver) after completion of
12 Week Assessment or whenever their participation in the study has ended.
Learn More About These Conditions
More information about Dermatitis, Atopic
Trial Not Found
The study you are looking for is not active at this time.
Return to Search